<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03317093</url>
  </required_header>
  <id_info>
    <org_study_id>CHAVANET BASILEA 2016</org_study_id>
    <nct_id>NCT03317093</nct_id>
  </id_info>
  <brief_title>Open and Exploratory Trial to Investigate the Pharmacokinetic of Ceftobiprole Medocaril in Patients With CSF Device</brief_title>
  <acronym>BASILE</acronym>
  <official_title>Open and Exploratory Trial to Investigate the Pharmacokinetic of Ceftobiprole Medocaril in Patients With CSF Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ceftobiprole is a very active new cephalosporin on staphylococci resistant to methicillin&#xD;
      (SEMR: Staphylococcus epidermidis Resistant to Meticillin, SAMR: Staphylococcus aureus&#xD;
      Resistant to Meticillin) and / or vancomycin; it is also very active on pneumococci resistant&#xD;
      to penicillin and / or 3rd generation cephalosporins. This new drug has AMM in nosocomial&#xD;
      respiratory infections, Animal work shows the efficacy of ceftobiprole in gram negative&#xD;
      bacillus meningeal infections.&#xD;
&#xD;
      The rationale of this study is based on the antibacterial spectrum of ceftobiprole, which&#xD;
      would therefore be useful in the treatment of staphylococcal bacterial meningitis resistant&#xD;
      patients (SEMR or SAMR) encountered in intensive care and / or neurosurgery and in the&#xD;
      treatment of pneumococcal meningitis.&#xD;
&#xD;
      To validate these possibilities, it is necessary to know the concentrations of ceftobiprole&#xD;
      in the meningeal space.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 29, 2018</start_date>
  <completion_date type="Actual">November 4, 2019</completion_date>
  <primary_completion_date type="Actual">October 21, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of concentration of ceftobiprole in blood</measure>
    <time_frame>Before and immediately the end of the perfusion and then at 0.5, 1, 3, 6, 12 and 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of concentration of ceftobiprole in cerebrospinal fluid</measure>
    <time_frame>Before and immediately the end of the perfusion and then at 0.5, 1, 3, 6, 12 and 24 hours</time_frame>
  </primary_outcome>
  <enrollment type="Actual">5</enrollment>
  <condition>Inflamed Meninges</condition>
  <condition>Suspected Meningitis</condition>
  <condition>Ventriculitis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftobiprole Medocaril</intervention_name>
    <description>1 single intravenous dose of 500 mg of Mabelio (Ceftobiprole Medocaril) perfused for 2 hours at D0</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood samples and cerebrospinal fluid</intervention_name>
    <description>Before and immediately before the end of the perfusion and then at 0.5h, 1h, 3h, 6h, 12h and 24h.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients (&gt; 18 years)&#xD;
&#xD;
               -  Provision of informed consent prior to any study specific procedures&#xD;
&#xD;
               -  Female patients of childbearing potential may be entered if pregnancy testing is&#xD;
                  negative and the patient agrees to abstain from procreational sexual intercourse&#xD;
                  or must use double-barrier contraceptive measures for the duration of the study&#xD;
&#xD;
          -  Presence of an indwelling external CSF access device (ventriculostomy or lumbar drain)&#xD;
&#xD;
          -  Presence of inflamed meninges as a result of documented or suspected meningitis or&#xD;
             ventriculitis. Patients with both clinical symptoms (fever, headache, meningismus, and&#xD;
             altered mentation) and laboratory parameters (CSF leukocytosis, defined as a CSF white&#xD;
             blood cell count [WBC] of &gt;103, elevated CSF protein, defined as CSF protein of &gt;1g/l,&#xD;
             reduced CSF glucose, defined as CSF glucose of &lt;0.3g/l, or a positive CSF Gram stain&#xD;
             or culture) indicative of CNS infection were deemed to have definitive bacterial&#xD;
             meningitis/ventriculitis. Inflamed meninges were defined as the presence of &gt;5&#xD;
             leukocytes/mm3 of CSF.&#xD;
&#xD;
          -  Person with antibacterial treatment (including treatment for the current meningitis or&#xD;
             ventriculitis)&#xD;
&#xD;
          -  Glycemia above 3 mmol/l and below 10 mmol/l&#xD;
&#xD;
          -  Natremia below 145 mmol/l&#xD;
&#xD;
          -  Capnia below 45 mmHg&#xD;
&#xD;
          -  No other patient included within 72 hours from D0 (treatment period) of the previous&#xD;
             patient&#xD;
&#xD;
          -  Agreement of the scientific committee&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypersensitivity to MABELIO® (ceftobiprole) or to one of its excipient or another 3rd&#xD;
             cephalosporin&#xD;
&#xD;
          -  Hypersensitivity to cephalosporin&#xD;
&#xD;
          -  Immediate and severe hypersensitivity to β-lactam antimicrobial other than Mabelio and&#xD;
             other cephalosporins&#xD;
&#xD;
          -  Pregnant or breast feeding women&#xD;
&#xD;
          -  Renal insufficiency defined as creatinine clearance &lt; 50 mL/min&#xD;
&#xD;
          -  Patient with creatinine clearance &gt; 150 mL/min&#xD;
&#xD;
          -  Patients with conditions known or suspected to alter pharmacokinetics (i.e., burn or&#xD;
             cystic fibrosis patients)&#xD;
&#xD;
          -  Refusal to participate&#xD;
&#xD;
          -  Person not affiliated to the social security&#xD;
&#xD;
          -  Absolute necessity of immediate removing the device&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU Dijon Bourgogne</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>October 18, 2017</study_first_submitted>
  <study_first_submitted_qc>October 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2017</study_first_posted>
  <last_update_submitted>September 14, 2020</last_update_submitted>
  <last_update_submitted_qc>September 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ceftobiprole</mesh_term>
    <mesh_term>Ceftobiprole medocaril</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

